Tumor-associated glycoprotein 72 (TAG72) is a cell surface glycoprotein that functions similar to an MUC and is often overexpressed in and shed from pancreas cancer (PC). It is known to be a better prognostic indicator than CA19.9 or CEA. Despite this and the fact that Indium-111 satumomab pendetide, a derivative of the anti-TAG72 antibody B72.3, was the first monoclonal antibody to be approved for tumor imaging, other attempted applications of anti-TAG72 mAbs fizzled out.